| PE01.63LB | "…I am here going strong": HIV-positive adolescents' perspectives on the influence of Operation Triple Zero initiative on HIV adherence and viral load suppression in Kisumu, Kenya | E-poster | Behavioural and social science research |
| OA07.02 | “I just decided to stop:” Understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya and its implications for a public health approach to prevention | Oral Abstract Session | Behavioural and social science research |
| PE02.09 | 35O22 and VRC44 define a new highly glycan-dependent multidonor class of HIV-1 gp120:gp41 interface-directed bnAbs | E-poster | Broadly neutralizing antibodies |
| PE06.08 | A functional performance and acceptability study of the Wondaleaf female condom | E-poster | Contraception, pregnancy and HIV prevention (incl. PMTCT) |
| PE02.17LB | A lineage of exceptionally potent and broad BnAbs with ultralong CDRH3 from vaccinated cows focus low-mutation rate from germline into a globular knob contacting the CD4bs | E-poster | Broadly neutralizing antibodies |
| OA11.02 | A multi-country investigation of Pre-Exposure Prophylaxis preferences among young people at risk of HIV in sub-Saharan Africa | Oral Abstract Session | Humoral immunity |
| PE08.07 | A new multipurpose vaginal ring for prevention of HIV and treatment of bacterial vaginosis | E-poster | Delivery technologies: novel approaches, formulation and multi-purpose |
| OA06.05 | A phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginally | Oral Abstract Session | Clinical trial results |
| PE06.05 | A randomized group antenatal care pilot showed increased partner communication and partner HIV testing during pregnancy in Malawi and Tanzania | E-poster | Contraception, pregnancy and HIV prevention (incl. PMTCT) |
| OA16.05 | A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026) | Oral Abstract Session | Pharmacology/PK and PD studies |